Skip to content
← All treatment topics

TREATMENT READING

Hodgkin Lymphoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

68 sections
  1. Adverse Long-Term Effects of Therapy
  2. Second malignancies
  3. Solid tumors
  4. Hematologic cancers
  5. Other adverse long-term effects
  6. Treatment Option Overview for HL
  7. Chemotherapy
  8. Radiation Therapy
  9. Treatment of Early Favorable Classic HL
  10. Treatment Options for Early Favorable Classic HL
  11. Chemotherapy with or without radiation therapy
  12. Treatment of Early Unfavorable Classic HL
  13. Treatment Options for Early Unfavorable Classic HL
  14. Chemotherapy with or without radiation therapy
  15. Treatment of Advanced Classic HL
  16. Treatment Options for Advanced Classic HL
  17. Chemotherapy with or without nivolumab or brentuximab vedotin
  18. Treatment of Recurrent Classic HL
  19. Treatment Options for Recurrent Classic HL
  20. Pembrolizumab or nivolumab (alone or with chemotherapy)
  21. Brentuximab vedotin
  22. Brentuximab vedotin plus nivolumab
  23. Chemotherapy with stem cell transplant
  24. Combination chemotherapy
  25. Radiation therapy
  26. Summary for sequencing therapies for recurrent classic HL
  27. Treatment of Nodular Lymphocyte–Predominant HL (NLPHL)
  28. Treatment Options for NLPHL
  29. Watchful waiting/active surveillance
  30. Radiation therapy
  31. Chemotherapy
  32. Rituximab
  33. Follow-Up
  34. Certain factors affect prognosis (chance of recovery) and treatment options.
  35. Hodgkin lymphoma may be grouped for treatment as follows:
  36. Early Favorable
  37. Early Unfavorable
  38. Advanced
  39. Hodgkin lymphoma can recur (come back) after it has been treated.
  40. Treatment Option Overview
  41. Key Points
  42. There are different types of treatment for patients with Hodgkin lymphoma.
  43. Patients with Hodgkin lymphoma should have their treatment planned by a team of health care providers with expertise in treating lymphomas.
  44. Treatment for Hodgkin lymphoma may cause side effects.
  45. The following types of treatment are used:
  46. Chemotherapy
  47. Radiation therapy
  48. Targeted therapy
  49. Immunotherapy
  50. Chemotherapy with stem cell transplant
  51. For patients with nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), treatment options also include:
  52. Watchful waiting
  53. Active surveillance
  54. For pregnant patients with Hodgkin lymphoma, treatment options also include:
  55. Watchful waiting
  56. Steroid therapy
  57. New types of treatment are being tested in clinical trials.
  58. Patients may want to think about taking part in a clinical trial.
  59. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  60. Follow-up care may be needed.
  61. Treatment of Early Favorable Classic Hodgkin Lymphoma
  62. Treatment of Early Unfavorable Classic Hodgkin Lymphoma
  63. Treatment of Advanced Classic Hodgkin Lymphoma
  64. Treatment of Recurrent Classic Hodgkin Lymphoma
  65. Treatment of Nodular Lymphocyte–Predominant Hodgkin Lymphoma (NLPHL)
  66. Treatment of Hodgkin Lymphoma During Pregnancy
  67. Hodgkin Lymphoma During the First Trimester of Pregnancy
  68. Hodgkin Lymphoma During the Second or Third Trimester of Pregnancy

Health professional · General Information About Hodgkin Lymphoma (HL)

Adverse Long-Term Effects of Therapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Patients who complete therapy for HL are at risk of developing long-term side effects, ranging from direct damage to organ function or the immune system to second malignancies. For the first 15 years after treatment, HL is the main cause of death. By 15 to 20 years after therapy, the cumulative mortality from a second malignancy, cardiovascular disease, or pulmonary fibrosis exceeds the cumulative mortality from HL.[20-23] This risk of developing a second malignancy is even higher for individuals with a family history of cancer.[24]

Sources: 20 · 23 · 24

Compared with the general population, long-term survivors of HL have a significantly lower life expectancy.[25] A multicenter cohort study of 4,919 patients treated between 1965 and 2000 and before age 51 years had a median follow-up of 20.2 years. Patients with HL had an absolute excess mortality (AEM) of 123 excess deaths per 10,000 person-years. This risk (standardized mortality ratio, 5.2; 95% confidence interval [CI], 4.2–6.5; AEM, 619) was maintained for 40-year survivors.[25] For example, at age 54 years, the cumulative mortality of 20.0% for HL survivors was commensurate with that of a 71-year-old person from the general population. While mortality from HL dropped precipitously from 1965 to 2000, solid tumor mortality did not change over that time.[25]

Sources: 25 · 25 · 25

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · General Information About Hodgkin Lymphoma (HL) / Adverse Long-Term Effects of Therapy

Second malignancies

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Recommendations for screening for secondary malignancies or follow-up of long-term survivors are consensus based and not derived from randomized trials.[26]

Sources: 26

Health professional · General Information About Hodgkin Lymphoma (HL) / Adverse Long-Term Effects of Therapy / Second malignancies

Solid tumors

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

An increase in second solid tumors has also been observed, especially mesothelioma and cancers of the lung, breast, thyroid, bone/soft tissue, stomach, esophagus, colon and rectum, uterine cervix, and head and neck.[27-34] These tumors occur primarily after radiation therapy or with combined-modality treatment (especially when involving mechlorethamine or procarbazine), and approximately 75% occur within radiation ports. The risk of developing a second solid tumor (cumulative incidence of a second cancer) increases with time after treatment.

Sources: 27 · 34

At 15-years of follow-up, the risk is approximately 13%.[30]

Sources: 30

At 20-years of follow-up, the risk is approximately 17%.[35]

Sources: 35

At 25-years of follow-up, the risk is approximately 22%.[27,36]

Sources: 27 · 36

At 40-years of follow-up, the risk is approximately 48%.[37]

Sources: 37

In a cohort of 18,862 5-year survivors from 13 population-based registries, the younger patients had elevated risks for breast, colon, and rectal cancers for 10 to 25 years before the ages when routine screening is recommended in the general population.[29] Even with involved-field doses of 15 Gy to 25 Gy, sarcomas, breast cancers, and thyroid cancers occurred with similar incidence in young patients, compared with those receiving higher-dose radiation.[35]

Sources: 29 · 35

Lung cancer and breast cancer are among the most-common second solid tumors that develop after therapy for HL.

Lung cancer. Lung cancer is seen with increased frequency, even after chemotherapy alone, and the risk of this cancer increases with cigarette smoking.[38-41] In a retrospective Surveillance, Epidemiology, and End Results (SEER) Program analysis, stage-specific survival was decreased by 30% to 60% in HL survivors, compared with patients with de novo non-small cell lung cancer.[42]

Sources: 38 · 41 · 42

Breast cancer. Breast cancer is seen with increased frequency after radiation therapy or combined-modality therapy.[27,28,43-45] The risk appears greatest for females treated with radiation before age 30 years, especially for girls close to menarche.[46] The incidence of breast cancer increases substantially after 15 years of posttherapy follow-up.[27,47,48] In a cohort of 1,964 female 5-year HL survivors treated between 1975 and 2008, doxorubicin also increased breast cancer risk independent of age at first treatment or prior chest radiation therapy.[49] Survivors who received more than 200 mg/m2 of doxorubicin had a 1.5-fold increased risk (95% CI, 1.08–2.10) versus survivors who did not receive doxorubicin. In two case-control studies of 479 patients who developed breast cancer after therapy for HL, cumulative absolute risks for developing breast cancer were calculated as a function of radiation therapy dose and the use of chemotherapy.[50,51] With a 30-year to 40-year follow-up, cumulative absolute risks of breast cancer with exposure to radiation range from 8.5% to 39.6%, depending on age at diagnosis. These cohort studies show a continued increase in cumulative excess risk of breast cancer beyond 20 years of follow-up.[50,51]In a nested case-control study and subsequent cohort study, patients who received both chemotherapy and radiation therapy had a statistically significant lower risk of developing breast cancer than did those treated with radiation therapy alone.[43,52] Reaching early menopause with fewer than 10 years of intact ovarian function appeared to account for the reduction in risk among patients who received combined-modality therapy.[52] Reduction of radiation volume also decreased the risk of breast cancer after HL.[52]

Sources: 27 · 28 · 43 · 45 · 46 · 27 · 47 · 48 · 49 · 50 · 51 · 50 · 51 · 43 · 52 · 52 · 52

Late effects of autologous stem cell transplant for failure of induction chemotherapy include second malignancies, hypothyroidism, hypogonadism, herpes zoster, depression, and cardiac disease.[53]

Sources: 53

Health professional · General Information About Hodgkin Lymphoma (HL) / Adverse Long-Term Effects of Therapy / Second malignancies

Hematologic cancers

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Acute myelogenous leukemia (AML). Acute nonlymphocytic leukemia may occur in patients treated with combined-modality therapy or with combination chemotherapy alone, especially with increased exposure to alkylating agents.[30,54]

Sources: 30 · 54

Acute myelogenous leukemia (AML). Acute nonlymphocytic leukemia may occur in patients treated with combined-modality therapy or with combination chemotherapy alone, especially with increased exposure to alkylating agents.[30,54]

At 10 years after therapy with regimens containing MOPP (mechlorethamine, vincristine, procarbazine, and prednisone), the risk of AML is approximately 3%, with the peak incidence occurring 5 to 9 years after therapy.[30,54] The risk of acute leukemia at 10 years after therapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) appears to be less than 1%.[55]

Sources: 30 · 54 · 55

A population-based study of more than 35,000 survivors during a 30-year time span identified 217 patients who developed AML. The excess absolute risk (EAR) was significantly higher for older patients (>35 years at diagnosis) than for younger survivors (EAR, 9.9 vs. 4.2 per 10,000 patient-years, P < .001).[56]

Sources: 56

Health professional · General Information About Hodgkin Lymphoma (HL) / Adverse Long-Term Effects of Therapy

Other adverse long-term effects

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment of HL also affects the endocrine, cardiac, pulmonary, skeletal, and immune systems. Chronic fatigue can be a debilitating symptom for some long-term survivors.[57] A retrospective survey of 20,007 patients with early- and advanced-stage classical HL treated between 2000 and 2016 (i.e., the era in which ABVD became the preferred frontline chemotherapy regimen) showed 1,321 deaths not attributable to lymphoma (39% of total deaths). Heart disease (estimated EAR: 6.6 per 10,000 patient-years, standardized mortality ratio, 1.7 for early-stage disease and 15.1 per 10,000 patient-years, standardized mortality ratio, 2.1 for advanced-stage disease) and infection (estimated EAR: 3.1 per 10,000 patient-years, standardized mortality ratio, 2.2 for early-stage disease and 10.6 per 10,000 patient-years, standardized mortality ratio, 3.9 for advanced-stage disease) were the leading causes of death, especially in patients older than 60 years.[58]

Sources: 57 · 58

Infertility. A toxic effect that is primarily related to chemotherapy is infertility, usually after regimens containing MOPP or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone).[59-61] After six to eight cycles of BEACOPP, most men had testosterone levels within reference range; however, 82% of women younger than 30 years recovered menses (mostly within 12 months), but only 45% of women older than 30 years recovered menses.[62] ABVD appears to spare long-term testicular and ovarian function.[60,63,64] Increasing age and alkylator-based regimens are the two major factors increasing the risk of premature ovarian insufficiency.[62,65,66] A prospective evaluation of gonadal function embedded in the randomized Response-Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL) study for patients with newly diagnosed advanced-stage HL found good recovery of anti-Müllerian hormone concentration and reduction in follicle-stimulating hormone after ABVD or AVD (doxorubicin, vinblastine, dacarbazine), but less recovery after BEACOPP and for women older than 35 years.[65] A PET scan-adapted treatment regimen to reduce the use of BEACOPP also resulted in less infertility and gonadal dysfunction.[67] While cryopreservation of oocytes or sperm remains the first choice for preservation of fertility, luteinizing hormone-releasing hormone agonists can be tried in this setting, although efficacy for patients with HL has not been confirmed as has been confirmed for patients with breast cancer.[68] A national Danish registry of 793 HL survivors showed that patients who did not have a relapse had similar parenthood rates to the general population, but assistive reproduction methods were required more often for HL survivors (male, 21.6% vs. 6.3%; female, 13.6% vs. 5.5%; P ≤ .001 for both comparisons).[69]

Sources: 59 · 61 · 62 · 60 · 63 · 64 · 62 · 65 · 66 · 65 · 67 · 68 · 69

Hypothyroidism. Hypothyroidism is a late complication primarily related to radiation therapy.[70-72] Long-term survivors who receive radiation therapy to the neck are followed up with annual thyroid-stimulating hormone testing.

Sources: 70 · 72

Cardiac disease. A late complication primarily related to radiation therapy is cardiac disease, the risk of which may persist for over 30 years after the first treatment.[70,73-81] The EAR of fatal cardiovascular disease ranges from 11.9 to 48.9 per 10,000 patient-years and is mostly attributable to fatal myocardial infarction (MI).[73-75,77] A retrospective survey of over 6,000 patients with HL treated in trials between 1964 and 2004 found that cardiac exposure to radiation and use of doxorubicin were significant predictors of ischemic heart disease, congestive heart failure, arrhythmias, and vascular disease.[79] In a cohort of 7,033 patients with HL, MI mortality risk persisted for 25 years after first treatment with supradiaphragmatic radiation therapy (dependent on the details of treatment planning), doxorubicin, or vincristine.[77,78] A nested case-control study of 2,617 5-year survivors of HL diagnosed before age 51 years and treated between 1965 and 1995 found that the 25-year risk of moderate to severe heart failure increased for patients receiving anthracyclines. The risk ranged from 11.2% for patients exposed to 0 Gy to 15 Gy radiation up to 32.9% for patients exposed to radiation equal or greater than 21 Gy.[82] The use of subcranial blocking did not reduce the incidence of fatal MI in a retrospective review, perhaps because of the exposure of the proximal coronary arteries to radiation.[74] Compared with a general matched population, HL patients treated with mediastinal radiation were at increased risk of complications, especially during cardiac surgery.[83] Risk prediction models rely on the dose of mediastinal radiation, smoking history, male sex, and anthracycline exposure to define the patients at highest risk.[81] These risk prediction models found that mediastinal radiation therapy combined with doxorubicin exposure conferred the highest risk, followed by mediastinal radiation therapy alone.[81]

Sources: 70 · 73 · 81 · 73 · 75 · 77 · 79 · 77 · 78 · 82 · 74 · 83 · 81 · 81

In the U.K. RAPID trial, performed between 2003 and 2010, 183 patients with early-stage HL were PET-negative but still received involved-field radiation therapy (IFRT) (20 Gy) after receiving ABVD.[80] The average predicted 30-year cardiovascular mortality was 5.02%, which included 3.52% expected in the general population, 0.94% EAR from the doxorubicin, and 0.56% from the IFRT. Since 2010, radiation therapy techniques have advanced by using smaller target volumes, lower-dose IFRT (20 Gy), deep inspiration breath holding, intensity-modulated radiation therapy, and proton beam therapy.[80] These techniques will need further evaluation to better assess cardiovascular risks from radiation therapy.

Sources: 80 · 80

Pulmonary impairment. Impairment of pulmonary function may occur as a result of mantle-field radiation therapy; this impairment is not usually clinically evident, and recovery in pulmonary testing often occurs after 2 to 3 years.[84] Pulmonary toxic effects from bleomycin as used in ABVD are seen in patients older than 40 years.[85]

Sources: 84 · 85

Bone necrosis. Avascular necrosis of bone has been observed in patients treated with chemotherapy and is most likely related to corticosteroid therapy.[86]

Sources: 86

Bacterial sepsis. Bacterial sepsis may occur rarely after splenectomy performed during staging laparotomy for HL;[87] it is much more common in children than in adults.

Sources: 87

Fatigue. Fatigue is a commonly reported symptom among patients who have completed chemotherapy and radiation therapy. In a case-control study design, most HL survivors reported significant fatigue lasting for more than 6 months after therapy, compared with age-matched controls. Quality-of-life questionnaires given to 5,306 patients on GHSG trials showed that 20% of patients complained of severe fatigue 5 years after therapy, and those patients had significantly increased problems with employment and financial stability.[88-90] For more information, see Fatigue.

Sources: 88 · 90 · Fatigue

Neurocognitive impairment. After a median of 23 years from diagnosis, 1,760 HL survivors treated in childhood were compared with 3,180 siblings. Significantly higher rates of memory loss (8.1% vs. 5.7%; P < .05), anxiety (7.0% vs. 5.4%; P < .05), unemployment (9.6% vs. 4.4%; P < .05), depression (9.1% vs. 7.0%; P < .05), and impaired physical quality of life (11.2% vs. 3.0%; P < .05) were reported.[91] Lower risks were associated with survivors who adhered to exercise guidelines and did not smoke, but the design of this study did not allow a cause-and-effect conclusion.

Sources: 91

Health professional

Treatment Option Overview for HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

After initial clinical staging for Hodgkin lymphoma (HL), patients with early favorable disease or early unfavorable disease are treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy with or without involved-field or nodal radiation.

Patients with advanced-stage disease are primarily treated with chemotherapy alone, although subsequent radiation therapy may be applied for initial bulky disease (≥10 cm mediastinal mass) or for residual adenopathy (>2.5 cm) with positive findings after a postchemotherapy positron emission tomography (PET) scan.[1] Treatment regimen preferences and application, as well as relative risks, differ regionally.

Sources: 1

Patients with HL who are older than 60 years may have more treatment-related morbidity and mortality; maintaining the dose intensity of standard chemotherapy may be difficult.[2,3] Other therapies have been proposed for older patients with lower tolerance for conventional regimens, but no randomized trials have been conducted with these regimens.[4] Twenty-seven previously untreated patients older than 60 years, judged by the investigator to be in poor condition and unable to undergo chemotherapy, received brentuximab vedotin. A 92% overall response rate and 73% complete remission rate were reported.[5][Level of evidence C3] Brentuximab vedotin has been combined with dacarbazine [6] or sequentially with AVD (doxorubicin, vinblastine, dacarbazine) [7], reporting acceptable toxicities in an older population. A retrospective review of 287 patients aged 60 years or older with early-stage favorable HL in two German Hodgkin Study Group (GHSG) trials (HD10 and HD13) showed increased bleomycin-induced lung toxicity with more than two cycles of exposure to bleomycin.[8]

Sources: 2 · 3 · 4 · 5 · Level of evidence C3 · 6 · 7 · 8

Table 3. Treatment Options for Hodgkin Lymphoma
Prognostic GroupTreatment Options
HL = Hodgkin lymphoma; NLPHL = nodular lymphocyte-predominant Hodgkin lymphoma.
Early favorable classic HLChemotherapy with or without radiation therapy
Early unfavorable classic HLChemotherapy with or without radiation therapy
Advanced classic HLChemotherapy with or without nivolumab or brentuximab vedotin
Recurrent classic HLPembrolizumab or nivolumab (alone or with chemotherapy)
Brentuximab vedotin
Brentuximab vedotin plus nivolumab
Chemotherapy with stem cell transplant
Combination chemotherapy
Radiation therapy
NLPHLWatchful waiting/active surveillance
Radiation therapy
Chemotherapy
Rituximab

Sources: Chemotherapy with or without radiation therapy · Chemotherapy with or without radiation therapy · Chemotherapy with or without nivolumab or brentuximab vedotin · Pembrolizumab or nivolumab (alone or with chemotherapy) · Brentuximab vedotin · Brentuximab vedotin plus nivolumab · Chemotherapy with stem cell transplant · Combination chemotherapy · Radiation therapy · Watchful waiting/active surveillance · Radiation therapy · Chemotherapy · Rituximab

Health professional · Treatment Option Overview for HL

Chemotherapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Table 4 describes the chemotherapy regimens used in the treatment of HL.

Table 4. Chemotherapy Regimens Used to Treat Hodgkin Lymphoma
Combination NameDrugs IncludedPrognostic Group
HL = Hodgkin lymphoma.
ABVDDoxorubicin, bleomycin, vinblastine, and dacarbazineEarly favorable classic HL
Early unfavorable classic HL
Advanced classic HL
BEACOPPBleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisoneEarly unfavorable classic HL
Advanced classic HL
GVDGemcitabine, vinorelbine, and liposomal doxorubicinRecurrent classic HL
ICEIfosfamide, carboplatin, and etoposideRecurrent classic HL
MOPPMechlorethamine, vincristine, procarbazine, and prednisoneAdvanced classic HL

Sources: Early favorable classic HL · Early unfavorable classic HL · Advanced classic HL · Early unfavorable classic HL · Advanced classic HL · Recurrent classic HL · Recurrent classic HL · Advanced classic HL

Health professional · Treatment Option Overview for HL

Radiation Therapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Radiation therapy alone is almost never used to treat patients newly diagnosed with early favorable classic HL.[9] In HL, the appropriate dose of radiation alone is 20 Gy to 30 Gy to clinically uninvolved sites and 30 Gy to 36 Gy to regions of initial nodal involvement.[9-11] When mediastinal radiation will encompass the left side of the heart or will increase breast cancer risk in young female patients, proton therapy may be considered to reduce the radiation dose to organs at risk.[12] When used as a single modality, radiation therapy is delivered to the neck, chest, and axilla (mantle field) and then to an abdominal field to treat para-aortic nodes and the spleen (splenic pedicle). In some patients, pelvic nodes are treated with a third field. The three fields constitute total nodal radiation therapy. In some cases, the pelvic and para-aortic nodes are treated in a single field called an inverted Y.[9-11]

Sources: 9 · 9 · 11 · 12 · 9 · 11

Health professional

Treatment of Early Favorable Classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Patients are designated as having early favorable classic Hodgkin lymphoma (HL) when they have clinical stage I or stage II disease and none of the following adverse prognostic factors:

B symptoms (unexplained fever ≥38°C, soaking night sweats, unexplained weight loss ≥10% within 6 months).

Extranodal disease.

Bulky disease (≥10 cm or >33% of the chest diameter on chest x-ray).

Three or more sites of nodal involvement.

Sedimentation rate of 50 mm/h or higher.

Health professional · Treatment of Early Favorable Classic HL

Treatment Options for Early Favorable Classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for early favorable classic HL include:

Chemotherapy with or without radiation therapy.

Sources: Chemotherapy with or without radiation therapy

Health professional · Treatment of Early Favorable Classic HL / Treatment Options for Early Favorable Classic HL

Chemotherapy with or without radiation therapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options include:

ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for three to six cycles.[1]

Sources: 1

ABVD for two to four cycles plus involved-field radiation therapy (IFRT) (20 Gy or 30 Gy).

Radiation therapy alone in certain circumstances (such as for older adults with absolute contraindications for using chemotherapy).[2,3]

Sources: 2 · 3

Historically, radiation therapy alone was the primary treatment for patients with early favorable classic HL, often after confirmatory negative staging laparotomy.

The late mortality from solid tumors (especially in the lung, breast, gastrointestinal tract, and connective tissue) and cardiovascular disease makes radiation therapy a less-attractive option for the best-risk patients, who have the highest probability of cure and long-term survival.[4-8] Clinical trials have focused on regimens with chemotherapy and IFRT or with chemotherapy alone.[1]

Sources: 4 · 8 · 1

Evidence (chemotherapy and/or radiation therapy):

For patients with early favorable classic HL, the following four trials established ABVD alone for four cycles or ABVD for two cycles plus 20 Gy of IFRT.

A randomized, prospective trial from the National Cancer Institute of Canada involving 123 patients with early favorable classic HL compared ABVD for four to six cycles with subtotal nodal radiation.[9][Level of evidence A1]

Sources: 9 · Level of evidence A1

A randomized, prospective trial from the National Cancer Institute of Canada involving 123 patients with early favorable classic HL compared ABVD for four to six cycles with subtotal nodal radiation.[9][Level of evidence A1]

With a median follow-up of 11.3 years, no difference was observed in event-free survival rates (89% vs. 86%; P = .64) or in overall survival rates (OS) (98% vs. 98%; P = .95).

A randomized study from the Milan Cancer Institute of patients with clinical early-stage HL compared 4 months of ABVD followed by IFRT with 4 months of ABVD followed by extended-field radiation therapy (EFRT).[10][Level of evidence B1]

Sources: 10 · Level of evidence B1

A randomized study from the Milan Cancer Institute of patients with clinical early-stage HL compared 4 months of ABVD followed by IFRT with 4 months of ABVD followed by extended-field radiation therapy (EFRT).[10][Level of evidence B1]

The results showed similar OS and freedom from progression of disease with a 10-year median follow-up, but the study had inadequate statistical power to determine noninferiority of IFRT versus EFRT.

In the HD10 trial, the German Hodgkin Study Group (GHSG) randomly assigned 1,190 patients with early favorable HL to receive one of the following:[11,12][Level of evidence A1]The following results were observed for the trial:

Sources: 11 · 12 · Level of evidence A1

In the HD10 trial, the German Hodgkin Study Group (GHSG) randomly assigned 1,190 patients with early favorable HL to receive one of the following:[11,12][Level of evidence A1]The following results were observed for the trial:

Two cycles of ABVD plus 30 Gy of IFRT.

Two cycles of ABVD plus 20 Gy of IFRT.

Four cycles of ABVD plus 30 Gy of IFRT.

Four cycles of ABVD plus 20 Gy of IFRT.

With an 8.2-year median follow-up, no differences were observed (hazard ratio [HR], 1.0; 95% confidence interval [CI], 0.6–1.5) in 10-year progression-free survival (PFS) rates (87%) or OS rates (94%) for all four groups.

A follow-up study by the GHSG (HD13 trial) compared modified versions of ABVD with elimination of dacarbazine, bleomycin, or both in combination with 30 Gy of radiation therapy in 1,502 patients with early favorable HL.[13]

Sources: 13

A follow-up study by the GHSG (HD13 trial) compared modified versions of ABVD with elimination of dacarbazine, bleomycin, or both in combination with 30 Gy of radiation therapy in 1,502 patients with early favorable HL.[13]

After 5 years, freedom from treatment failure was significantly worse when dacarbazine, bleomycin, or both were omitted.

This trial suggests that ABVD remains the standard chemotherapy regimen.

Other trials have investigated the role of positron emission tomography (PET) scans for early favorable HL.

Three prospective randomized trials (EORTC/LYSA/FIL H10 [NCT00433433][14,15]; RAPID [NCT00943423][16,17]; and GHSG HD16 [NCT00736320][18]) of 2,889 patients with early-stage disease investigated the use of PET‒computed tomography (CT) scans to modify therapy.[14-18]

Sources: EORTC/LYSA/FIL H10 · 14 · 15 · RAPID · 16 · 17 · GHSG HD16 · 18 · 14 · 18

Three prospective randomized trials (EORTC/LYSA/FIL H10 [NCT00433433][14,15]; RAPID [NCT00943423][16,17]; and GHSG HD16 [NCT00736320][18]) of 2,889 patients with early-stage disease investigated the use of PET‒computed tomography (CT) scans to modify therapy.[14-18]

Among patients with early favorable HL who had negative PET-CT scan results (Deauville score of 1 or 2) after two or three cycles of ABVD, radiation therapy could be omitted with no significant loss of OS in all three trials.[14,16,18][Level of evidence B1]However, two of the trials showed an increased risk of relapse when radiation therapy was omitted. In the GHSG HD16 trial, for the 628 patients with PET2-negative disease (PET after two cycles of ABVD), the 5-year PFS rate was 93.4% (95% CI, 90.4%–96.5%) with combined modality therapy and 86.1% (95% CI, 81.4%–90.0%) with ABVD alone (HR, 1.78; 95% CI, 1.02–3.12).[18] A subsequent analysis of the GHSG HD16 trial showed that most of the recurrences occurred in the proposed radiation field.[15] In the EORTC/LYSA/FIL H10 trial, the 10-year PFS rate was 98.8% with three cycles of ABVD plus radiation therapy and 85.4% with four cycles of ABVD without radiation therapy (HR, 13.2; 95% CI, 3.1–55.8; P < .001).[17]In summary, this 7% to 13% difference in PFS without a difference in OS can be seen either as a mandate to combine radiation therapy with ABVD to avoid recurrences or as a rationale to give four or more cycles of ABVD when omitting radiation therapy.

Sources: 14 · 16 · 18 · Level of evidence B1 · 18 · 15 · 17

ABVD was given for three cycles (six doses) in the RAPID study,[16] for four cycles (eight doses) in the EORTC/LYSA/FIL H10 study,[14] and for two cycles (four doses) in the GHSG HD16 study [18] when applied without radiation therapy.

Sources: RAPID · 16 · EORTC/LYSA/FIL H10 · 14 · GHSG HD16 · 18

None of the studies randomly assigned therapy for positive results from an interim PET-CT scan (Deauville score of 3, 4, or 5) after two or three cycles of ABVD because this occurred in only 15% to 25% of the patients studied. One of the studies (RAPID) added an extra cycle of ABVD and IFRT to 30 Gy,[16] another study (EORTC H10F) switched to BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone)–escalated therapy for two cycles plus involved nodal radiation therapy to 30 Gy,[14] and the other study (GHSG HD16) added IFRT to 30 Gy.[18]In the RAPID study (NCT00943423), patients with postchemotherapy PET-CT Deauville scores of 5 (uptake ≥3 times maximum liver uptake) had inferior 5-year PFS rates (61.9%; 95% CI, 41.1%–82.7%) and 5-year OS rates (85.2%; 95% CI, 69.7%–100%) (P = .002) when compared with patients with Deauville scores of 1 to 4 (P < .001).[19]

Sources: 16 · 14 · 18 · RAPID · 19

Older patients with early favorable HL have also been studied.

In 287 patients older than 60 years or with early favorable disease, a retrospective review of pulmonary toxicity in the HD10 and HD13 trials showed the following:[20]

Sources: 20

In 287 patients older than 60 years or with early favorable disease, a retrospective review of pulmonary toxicity in the HD10 and HD13 trials showed the following:[20]

Two cycles of ABVD plus IFRT (137 patients): 2% pulmonary toxicity.

Two cycles of AVD (omitting bleomycin) plus IFRT (82 patients): 2% pulmonary toxicity.

Four cycles of ABVD plus IFRT (68 patients): 10% pulmonary toxicity.

For older patients (>60 years) with early favorable disease, when more than two cycles of ABVD are required, bleomycin may be omitted to avoid pulmonary toxicity.

Summary of early favorable classic HL:

ABVD alone for three to four cycles is recommended for patients with early favorable classical HL when the interim PET-CT scan results are negative after two or three cycles of chemotherapy.[21] These patients are also unlikely to ever have a relapse, so routine CT scans are not recommended in follow-up.

Sources: 21 · follow-up

With positive interim PET-CT scan results, extra cycles of ABVD and involved nodal radiation therapy are recommended.

A combined-modality approach with two cycles of ABVD and 20 Gy of IFRT can also be used for patients with early favorable classic HL.[21] In this situation, a PET-CT scan to assess response after completion of therapy would suffice.

Sources: 21

Health professional

Treatment of Early Unfavorable Classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Patients are designated as having early unfavorable classic Hodgkin lymphoma (HL) when they have clinical stage I or stage II disease and one or more of the following risk factors:

B symptoms (unexplained fever ≥38°C, soaking night sweats, unexplained weight loss ≥10% within 6 months).

Extranodal disease.

Bulky disease (≥10 cm or >33% of the chest diameter on chest x-ray).

Three or more sites of nodal involvement.

Sedimentation rate of 50 mm/h or higher.

A retrospective review found that infradiaphragmatic early-stage disease appears to have an inferior outcome compared with the more frequent (>90%) supradiaphragmatic disease, with a decrement in overall survival (OS) rates of 6% (91.5% vs. 97.6%; P < .001).[1][Level of evidence C2]

Sources: 1 · Level of evidence C2

Health professional · Treatment of Early Unfavorable Classic HL

Treatment Options for Early Unfavorable Classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for early unfavorable classic HL include:

Chemotherapy with or without radiation therapy.

Sources: Chemotherapy with or without radiation therapy

Health professional · Treatment of Early Unfavorable Classic HL / Treatment Options for Early Unfavorable Classic HL

Chemotherapy with or without radiation therapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options include:[2,3]

Sources: 2 · 3

Four cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) plus involved-field radiation therapy (IFRT) (20 Gy–30 Gy).[4-7]

Sources: 4 · 7

Six cycles of ABVD.[2,3]

Sources: 2 · 3

See Table 4 for a description of the chemotherapy regimens used to treat HL.

Sources: Table 4

Evidence (chemotherapy and radiation therapy):

A randomized, prospective trial from the National Cancer Institute of Canada (NCIC) involving 276 patients with early unfavorable HL compared ABVD for four to six cycles with ABVD for two cycles plus extended-field radiation therapy (EFRT).[2][Level of evidence A1]

Sources: 2 · Level of evidence A1

A randomized, prospective trial from the National Cancer Institute of Canada (NCIC) involving 276 patients with early unfavorable HL compared ABVD for four to six cycles with ABVD for two cycles plus extended-field radiation therapy (EFRT).[2][Level of evidence A1]

With a median follow-up of 11.3 years, the freedom from progression score favored combined-modality therapy (86% vs. 94%; P = .006), but the OS rate was better for ABVD alone (92% vs. 81%; P = .04).

The trend toward a worse survival for the combined-modality arm was attributed to excess secondary malignancies and cardiovascular deaths. In this trial, the EFRT used higher doses and significantly larger exposure to body sites than are employed in current practice.

This trial established that six cycles of ABVD can be used alone and that long-term complications from radiation therapy can negate differences for progression-free survival (PFS).

In the HD11 trial, the German Hodgkin Study Group (GHSG) randomly assigned 1,395 patients with early unfavorable HL to receive one of the following:The following results were observed:

In the HD11 trial, the German Hodgkin Study Group (GHSG) randomly assigned 1,395 patients with early unfavorable HL to receive one of the following:The following results were observed:

Four cycles of ABVD plus 30 Gy of IFRT.

Four cycles of ABVD plus 20 Gy of IFRT.

Four cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) plus 30 Gy of IFRT.

Four cycles of BEACOPP plus 20 Gy of IFRT.

With an 8.8-year median follow-up, no differences were observed in OS rates (93%–96%) for all four groups.[8][Level of evidence A1]

Sources: 8 · Level of evidence A1

In the study arms using 30 Gy of IFRT, there was no difference in freedom from treatment failure between BEACOPP and ABVD (P = .65), but a significant difference against ABVD was seen for PFS when 20 Gy of IFRT was used (10-year PFS rate, 84% vs. 76%; hazard ratio (HR), 1.5; 95% confidence interval [CI], 1.0–2.1).[5][Level of evidence B1]

Sources: 5 · Level of evidence B1

In this trial, four cycles of ABVD plus 30 Gy of IFRT established this regimen as the preferred approach (or BEACOPP with 20 Gy of IFRT).

In the HD14 trial, the GHSG randomly assigned 1,528 patients with early unfavorable HL to receive either four cycles of ABVD plus 30 Gy of IFRT or two cycles of escalated BEACOPP followed by two cycles of ABVD plus 30 Gy of IFRT.[6][Level of evidence A1]

Sources: 6 · Level of evidence A1

In the HD14 trial, the GHSG randomly assigned 1,528 patients with early unfavorable HL to receive either four cycles of ABVD plus 30 Gy of IFRT or two cycles of escalated BEACOPP followed by two cycles of ABVD plus 30 Gy of IFRT.[6][Level of evidence A1]

With a median follow-up of 43 months, no difference was observed in OS.

In this trial, four cycles of ABVD plus 30 Gy of IFRT established this regimen as the preferred approach.

In the H9-U trial, the European Organisation for Research and Treatment of Cancer–Groupe d'Étude des Lymphomes de l'Adulte (EORTC/GELA) randomly assigned 808 patients with early unfavorable disease (including 40% with bulky disease) to receive one of the following:[7][Level of evidence A1]:The following results were observed:

Sources: 7 · Level of evidence A1

In the H9-U trial, the European Organisation for Research and Treatment of Cancer–Groupe d'Étude des Lymphomes de l'Adulte (EORTC/GELA) randomly assigned 808 patients with early unfavorable disease (including 40% with bulky disease) to receive one of the following:[7][Level of evidence A1]:The following results were observed:

Six cycles of ABVD plus 36 Gy of IFRT.

Four cycles of ABVD plus 36 Gy of IFRT.

Four cycles of BEACOPP plus 36 Gy of IFRT.

With a median follow-up of 64 months, no differences were observed (event-free survival rates, 89%–92%; P = .38; or OS rates, 91%–96%; P = .89).

Based on toxicities, four cycles of ABVD plus IFRT was established as the preferred regimen.

A multicenter nonrandomized study in 117 patients (most of whom had bulky disease) showed that four cycles of BV-AVD (brentuximab vedotin + doxorubicin, vinblastine, and dacarbazine) with or without involved-site radiation therapy is well-tolerated and effective.[9]

Sources: 9

A multicenter nonrandomized study in 117 patients (most of whom had bulky disease) showed that four cycles of BV-AVD (brentuximab vedotin + doxorubicin, vinblastine, and dacarbazine) with or without involved-site radiation therapy is well-tolerated and effective.[9]

With a median follow-up of 3.8 years, the overall 2-year PFS was 94% (95% CI, 89.7%–98.3%). The 2-year OS was 99.1% (97.3%– 100.0%).[9][Level of evidence C2]

Sources: 9 · Level of evidence C2

This pilot study requires confirmation, but the results may be reassuring when using the regimen for patients who cannot take bleomycin or need to limit anthracycline exposure.

Could the radiation therapy be omitted to minimize late morbidity and mortality from secondary solid tumors and from cardiovascular disease? [3]

Sources: 3

The NCIC study addressed this question in patients with early unfavorable HL. Although four to six cycles of ABVD alone had improved OS compared with a combined-modality approach, the use of EFRT in the combined-modality arm is excessive by current standards, and late effects will be magnified with these larger fields.[2] In addition, chemotherapy alone was 8% worse in freedom from disease progression compared with the combined-modality approach. An indirect comparison for using ABVD alone is that the 94% OS rate reported for patients with early unfavorable HL in the NCIC study [2] at 11 years is equivalent to the survival reported at 11 years in the GHSG's HD6 (NCT00002561), HD10 (NCT01399931), and HD11 (NCT0264953) trials using combined-modality therapy.[10] In addition, for the HD6 and HD10 trials, between the reports at 55 months and subsequently at 133 months, cardiovascular events doubled and solid tumor events tripled.[10]

Sources: 2 · 2 · HD6 · HD10 · HD11 · 10 · 10

A retrospective analysis of 215 patients treated with ABVD and more contemporary radiation therapy (20 Gy–30 Gy, limited field) was compared with a cohort of 860 individuals matched for age, sex, geographical region, and major medical diseases.[11] Excess morbidity was still seen in terms of second malignancies, cardiovascular disease, and respiratory disease (HR, 1.5–7.6), but at a lower rate than in reports using regimens and doses from earlier decades.[11]

Sources: 11 · 11

A Cochrane meta-analysis of 1,245 patients in five randomized clinical trials suggested improved survival for combined-modality therapy versus chemotherapy alone (HR, 0.40; 95% CI, 0.27–0.61).[12] However, the five randomized trials that were analyzed had inadequate follow-up to account for the late toxicities and increased mortality seen with radiation therapy after 10 years.

Sources: 12

Other trials have investigated the role of positron emission tomography‒computed tomography (PET-CT) scans for patients with early unfavorable HL.

A randomized prospective trial (EORTC HIOU) of 1,196 patients with early unfavorable HL investigated the use of PET-CT scans to modify therapy after two cycles of therapy.[13]This trial supports adding escalated BEACOPP to ABVD for patients with early unfavorable classic HL who have positive PET-CT results after two cycles.

Sources: 13

A randomized prospective trial (EORTC HIOU) of 1,196 patients with early unfavorable HL investigated the use of PET-CT scans to modify therapy after two cycles of therapy.[13]This trial supports adding escalated BEACOPP to ABVD for patients with early unfavorable classic HL who have positive PET-CT results after two cycles.

Among the 815 patients with negative PET-CT findings (Deauville score of 1 or 2) after two cycles of ABVD, the patients randomly assigned to receive six cycles of ABVD had inferior PFS rates compared with patients who received four cycles of ABVD plus involved nodal radiation therapy (94.7% vs. 99.2%; P = .026), but no difference in OS.[Level of evidence B1]

Sources: Level of evidence B1

The use of ABVD for six cycles is acceptable in the absence of radiation therapy for patients with early unfavorable classic HL who have negative PET-CT results after two cycles of ABVD, if one can accept a 5% rate of increased relapse, with no decrement in OS after salvage therapy.

In a follow-up report from this trial, 381 patients with positive PET-CT results (Deauville score of 3, 4, or 5) after two cycles of ABVD were randomly assigned to receive four cycles of ABVD plus 30 Gy of involved nodal radiation therapy versus two cycles of ABVD followed by two cycles of escalated BEACOPP plus 30 Gy of involved nodal radiation therapy.[14][Level of evidence A1]

Sources: 14 · Level of evidence A1

A randomized prospective trial (EORTC HIOU) of 1,196 patients with early unfavorable HL investigated the use of PET-CT scans to modify therapy after two cycles of therapy.[13]This trial supports adding escalated BEACOPP to ABVD for patients with early unfavorable classic HL who have positive PET-CT results after two cycles. › In a follow-up report from this trial, 381 patients with positive PET-CT results (Deauville score of 3, 4, or 5) after two cycles of ABVD were randomly assigned to receive four cycles of ABVD plus 30 Gy of involved nodal radiation therapy versus two cycles of ABVD followed by two cycles of escalated BEACOPP plus 30 Gy of involved nodal radiation therapy.[14][Level of evidence A1]

The 5-year PFS rate was 91% in the BEACOPP arm compared with 77% in the ABVD arm (P = .002).

The 5-year OS rate was 96% in the BEACOPP arm compared with 89% in the ABVD arm (P = .02).

A randomized prospective trial (GHSG HD17 [NCT01356680]) of 1,100 patients with early-stage unfavorable HL evaluated whether radiation therapy can be omitted in patients with a complete metabolic response (CMR) on PET-CT scan after two cycles of escalated BEACOPP and two cycles of regular-dose BEACOPP (2 + 2 regimen). Patients were randomly assigned to receive combined-modality therapy (n = 548) or PET4-guided therapy (n = 552). Combined-modality therapy included both the 2 + 2 regimen and involved-field radiation therapy. PET4-guided therapy included the 2 + 2 regimen for all patients and involved-node radiation therapy for the patients with a positive PET4 scan (n = 160). A total of 333 patients in the PET4-guided therapy group were PET4-negative and received chemotherapy alone.[15]

Sources: GHSG HD17 · 15

A randomized prospective trial (GHSG HD17 [NCT01356680]) of 1,100 patients with early-stage unfavorable HL evaluated whether radiation therapy can be omitted in patients with a complete metabolic response (CMR) on PET-CT scan after two cycles of escalated BEACOPP and two cycles of regular-dose BEACOPP (2 + 2 regimen). Patients were randomly assigned to receive combined-modality therapy (n = 548) or PET4-guided therapy (n = 552). Combined-modality therapy included both the 2 + 2 regimen and involved-field radiation therapy. PET4-guided therapy included the 2 + 2 regimen for all patients and involved-node radiation therapy for the patients with a positive PET4 scan (n = 160). A total of 333 patients in the PET4-guided therapy group were PET4-negative and received chemotherapy alone.[15]

With a median follow-up of 46.2 months, the 5-year PFS rate was 97.3% (95% CI, 94.5%–98.7%) for patients who received combined-modality therapy and 95.1% (95% CI, 92.0%–97.0%) for patients who received PET4-guided therapy (HR, 0.523; 95% CI, 0.23–1.21). The between-group difference was 2.2% (95% CI, -0.9% to 5.3%) and excluded the noninferiority margin of 8%.[15][Level of evidence B1]

Sources: 15 · Level of evidence B1

In the subgroup of PET4-negative patients who received chemotherapy alone, the difference in 5-year PFS was 1.7% (95% CI, -1.8% to 5.3%).

Omitting radiation therapy for patients in CMR after four cycles of BEACOPP-based chemotherapy did not significantly impair PFS.

A prospective phase II trial included 94 patients with early-stage (I/II) bulky disease (defined as mass >10 cm or >⅓ maximum intrathoracic diameter on chest x-ray). Patients received ABVD for two cycles, followed by interim PET (PET2) scan. PET-negative patients (78% of the total) were defined as Deauville 1, 2, or 3 and received two more cycles of ABVD. PET2-positive patients (Deauville 4 or 5, 22% of the total) received four cycles of escalated BEACOPP, followed by 30.6 Gy of IFRT.[16]

Sources: 16

A prospective phase II trial included 94 patients with early-stage (I/II) bulky disease (defined as mass >10 cm or >⅓ maximum intrathoracic diameter on chest x-ray). Patients received ABVD for two cycles, followed by interim PET (PET2) scan. PET-negative patients (78% of the total) were defined as Deauville 1, 2, or 3 and received two more cycles of ABVD. PET2-positive patients (Deauville 4 or 5, 22% of the total) received four cycles of escalated BEACOPP, followed by 30.6 Gy of IFRT.[16]

With a median follow-up of 60 months, the 3-year PFS rate was 93.1% in PET2-negative patients and 89.7% in PET2-positive patients. The 3-year OS rate was 98.6% in PET2-negative patients and 94.4% in PET2-positive patients.[16][Level of evidence C3]

Sources: 16 · Level of evidence C3

To summarize:

Most of the trials support using four cycles of ABVD plus 30 Gy of IFRT or involved nodal radiation therapy.[17]

Sources: 17

ABVD alone for six cycles is a reasonable alternative despite a 5% to 6% decrement in PFS because the long-term toxicities of adding radiation therapy will affect OS, which is the most important patient outcome.[17]

Sources: 17

For patients with a positive PET-CT (usually Deauville 4 or 5) after two cycles of ABVD, adding brentuximab vedotin while eliminating bleomycin can be considered. BEACOPP or clinical trials investigating the addition of brentuximab vedotin or checkpoint inhibitors in this setting would be indicated.

Radiation therapy may be omitted in patients with a negative PET-CT (Deauville 1) after two to four cycles of chemotherapy.

Patients with bulky disease (≥10 cm) or massive mediastinal involvement were excluded from most of the trials. On the basis of historical comparisons to chemotherapy or radiation therapy alone, these patients receive combined-modality therapy.[18-20][Level of evidence C2] A retrospective review published in a preliminary abstract reported on 194 patients with bulky disease who had PET-CT scans at the completion of chemotherapy; 112 of them had negative PET results (Deauville score of 1 or 2).[21] The observed 86% OS rate at 5 years suggests that radiation therapy can be excluded for patients with massive mediastinal disease who have negative PET-CT scan results after six cycles of therapy.[21][Level of evidence C2]

Sources: 18 · 20 · Level of evidence C2 · 21 · 21 · Level of evidence C2

Health professional

Treatment of Advanced Classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The following adverse prognostic factors for advanced classic Hodgkin lymphoma (HL) have been combined into the International Prognostic Score (IPS) for advanced-stage HL:[1]

Sources: 1

Albumin level lower than 40 g/L.

Hemoglobin level lower than 105 g/L.

Male sex.

Aged 45 years or older.

Stage IV disease.

White blood cell (WBC) count of 15 × 109/L or higher.

Absolute lymphocyte count lower than 0.6 × 109/L or a lymphocyte count higher than 8% of the total WBC count.

Table 5. Risk Factors and Survival Rates for Patients With Advanced Classic Hodgkin Lymphoma
No. of Risk Factors5-Year FFP (%)5-Year OS (%)
FFP = freedom from progression; No. = number; OS = overall survival.
08898
18497
28092
37491
46788
≥56273

Even the highest-risk patients in this index have a 5-year freedom from progression rate above 60% and a 5-year overall survival (OS) rate above 70%.[1]

Sources: 1

Health professional · Treatment of Advanced Classic HL

Treatment Options for Advanced Classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for advanced classic HL include:

Chemotherapy with or without immunotherapy or an antibody-drug conjugate.

Sources: Chemotherapy with or without immunotherapy or an antibody-drug conjugate

Chemotherapy with or without immunotherapy or an antibody-drug conjugate.

N-AVD (nivolumab [a checkpoint inhibitor] plus doxorubicin, vinblastine, and dacarbazine).

BV-AVD (brentuximab vedotin [an antibody-drug conjugate directed against CD30] plus doxorubicin, vinblastine, and dacarbazine).

ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).

Health professional · Treatment of Advanced Classic HL / Treatment Options for Advanced Classic HL

Chemotherapy with or without nivolumab or brentuximab vedotin

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The chemotherapy regimens N-AVD and BV-AVD are given for six cycles. These regimens have replaced ABVD, the previous standard regimen for three decades.[2,3] The ABVD regimen remains a viable option in cost-conscious settings.

Sources: 2 · 3

See Table 4 for a description of the chemotherapy regimens used to treat HL.

Sources: Table 4

Evidence (chemotherapy with or without nivolumab or brentuximab vedotin):

A randomized prospective trial (NCT03907488) enrolled 994 patients with previously untreated advanced-stage HL. The study compared BV-AVD with N-AVD.[4]

Sources: NCT03907488 · 4

A randomized prospective trial (NCT03907488) enrolled 994 patients with previously untreated advanced-stage HL. The study compared BV-AVD with N-AVD.[4]

With a median follow-up of 2.1 years, the 2-year progression-free survival (PFS) rate favored N-AVD over BV-AVD at 92% (95% confidence interval [CI], 89%–94%) versus 83% (95% CI, 79%–86%) (hazard ratio [HR], 0.45; 95% CI, 0.30–0.65; P = .001).[4][Level of evidence B1]

Sources: 4 · Level of evidence B1

Treatment discontinuation due to side effects was twice as likely for patients who received BV-AVD (22% vs. 11%), mainly because of peripheral sensory neuropathy. Grade 2 or higher sensory peripheral neuropathy occurred in 32% of patients who received BV-AVD and 3% of patients who received N-AVD.

A preplanned analysis, published in abstract form, included 97 patients aged 60 years or older. With a median follow-up of 12.1 months, the 1-year PFS favored N-AVD over BV-AVD at 93% versus 64% (HR, 0.35; 95% CI, 0.12–1.02; P = .022).[5] The BV-AVD regimen had substantially worse side effects including septicemia, peripheral sensory neuropathy, nausea, diarrhea, anorexia, and weight loss, compared with rash and hypothyroidism for N-AVD.[5]

Sources: 5 · 5

Based on the substantial PFS advantage across age, stage, and IPS score subgroups, as well as the reduced toxicity from avoiding bleomycin or brentuximab vedotin, N-AVD has become the treatment of choice for patients with stages III and IV HL.

A randomized prospective trial (NCT01712490) included 1,334 patients with previously untreated advanced-stage HL. The study compared ABVD with BV-AVD.[6]

Sources: NCT01712490 · 6

A randomized prospective trial (NCT01712490) included 1,334 patients with previously untreated advanced-stage HL. The study compared ABVD with BV-AVD.[6]

With a median follow-up of 73 months, the 6-year OS rate was 93.9% (95% CI, 91.6%–95.5%) for patients who received BV-AVD and 89.4% (95% CI, 86.6%–91.7%) for patients who received ABVD (HR, 0.59; 95% CI, 0.40–0.88; P = .009).[6][Level of evidence A1]

Sources: 6 · Level of evidence A1

With a median follow-up of 73 months, the 6-year PFS rate was 82.3% (95% CI, 79.1%–85.0%) for patients who received BV-AVD and 74.5% (95% CI, 70.8%–77.7%) for patients who received ABVD (HR, 0.68; 95% CI, 0.53–0.86; P = .002).[6]

Sources: 6

Among patients who received BV-AVD, there was significantly more grade 3 or 4 peripheral neuropathy (67% vs. 43%); however, there was more than 80% partial or complete recovery, with a median time to resolution of 16 weeks for BV-AVD and 10 weeks for ABVD. Pulmonary toxicity led to 11 deaths in the ABVD arm.

Although fertility was not directly assessed, pregnancies and live births subsequently occurred in both arms of the trial for female patients and female partners of the male patients.

BV-AVD can cost 50 times more than ABVD (in 2018).[7]

Sources: 7

BV-AVD is a new standard of care for patients with advanced-stage classic HL.

In multiple prospective trials and a meta-analysis, ABVD therapy for 6 to 8 months for patients with newly diagnosed advanced HL, showed equivalent OS when compared with other regimens (i.e., BEACOPP [bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone], escalated BEACOPP, Stanford V [doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, and prednisone], and MOPP-ABV [mechlorethamine, vincristine, procarbazine prednisone/doxorubicin, bleomycin, and vinblastine]).[8-15][Level of evidence A1]

Sources: 8 · 15 · Level of evidence A1

Multiple studies have addressed the role of radiation therapy consolidation after induction chemotherapy for advanced-stage HL.

Three prospective randomized trials did not show a benefit in OS from the addition of consolidative radiation therapy to chemotherapy for patients with advanced-stage disease.[16-18][Level of evidence A1]

Sources: 16 · 18 · Level of evidence A1

In a meta-analysis of 1,740 patients treated in 14 different trials, no improvement was observed in 10-year OS for patients with advanced-stage HL who received combined-modality therapy compared with chemotherapy alone.[19][Level of evidence C1]

Sources: 19 · Level of evidence C1

No survival advantage is known for the use of radiation consolidation for patients with massive mediastinal disease and advanced-stage disease.[20]A randomized prospective trial with a median follow-up of 5.9 years included 320 patients with advanced-stage HL and a large nodal mass (≥5 cm). Patients were randomly assigned to receive radiation therapy or no further treatment after six cycles of ABVD. For patients with a complete metabolic response on positron emission tomography (PET)–computed tomography (CT) after six cycles of ABVD, there was no difference in the 6-year PFS rate for patients who received radiation therapy (91%; 95% CI, 84%–99%) versus patients who received no further treatment (95%; 95% CI, 89%–100%, P = .62).[21][Level of evidence B1]

Sources: 20 · 21 · Level of evidence B1

The German Hodgkin Lymphoma Study Group HD15 trial showed that a negative PET scan after induction therapy with BEACOPP (escalated or every 14 days) for advanced-stage HL was highly predictive for a good outcome, even with the omission of consolidative radiation therapy (negative predictive value for PET was 94% [95% CI, 91%–97%]).[22] In the German Hodgkin Study Group HD18 trial (NCT00515554), PET scan negativity after two cycles (PET2) of escalated BEACOPP allowed reduction to four cycles of therapy instead of six or eight cycles because of the equivalent 5-year PFS (90.8% vs. 92.2%; difference 1.4%; 95% CI, -2.7 to 5.4).[23][Level of evidence B1] The HD18 trial established a Deauville score of 4 or 5 as PET2 positive based on a 3-year OS.[24]

Sources: 22 · HD18 · 23 · Level of evidence B1 · 24

Other trials have investigated the role of PET scans in patients with advanced classic HL.

A randomized prospective trial of 1,214 patients with advanced-stage HL (RATHL [NCT00678327]) investigated the use of PET-CT scans after two cycles of ABVD to modify therapy.[25,26] Patients with negative findings from a PET-CT scan (Deauville score of 1, 2, or 3) were randomly assigned to receive four more cycles of ABVD versus four cycles of AVD (doxorubicin, vinblastine, and dacarbazine).

Sources: RATHL · 25 · 26

A randomized prospective trial of 1,214 patients with advanced-stage HL (RATHL [NCT00678327]) investigated the use of PET-CT scans after two cycles of ABVD to modify therapy.[25,26] Patients with negative findings from a PET-CT scan (Deauville score of 1, 2, or 3) were randomly assigned to receive four more cycles of ABVD versus four cycles of AVD (doxorubicin, vinblastine, and dacarbazine).

With a median follow-up of 7.3 years for the 937 patients with negative PET-CT results, there was no difference in the 7-year OS rate (93.2%; 95% CI, 90.2%–95.3% for ABVD vs. 93.5%; 95% CI, 90.5%–95.5% for AVD).[26][Level of evidence A1]

Sources: 26 · Level of evidence A1

The absolute difference in the 3-year PFS rate (ABVD minus AVD) was 1.3% (95% CI, -3.0% to 4.7%), which falls within the predefined noninferiority margin. This meant that there was no PFS advantage for continuing bleomycin for PET-negative patients on the interim scan.

However, pulmonary toxicity was worse in the continued ABVD arm, with significantly more grade 3 or 4 respiratory events and worsened long-term diffusing capacity of the lung for carbon monoxide levels persisting beyond 1 year.

This study concluded that bleomycin may be omitted after the second cycle of ABVD if findings from the PET-CT scan are negative (Deauville score of 1, 2, or 3).

The patients with positive PET-CT scan results (Deauville score of 4 or 5) after two cycles of ABVD received BEACOPP.

A randomized prospective trial of 1,214 patients with advanced-stage HL (RATHL [NCT00678327]) investigated the use of PET-CT scans after two cycles of ABVD to modify therapy.[25,26] Patients with negative findings from a PET-CT scan (Deauville score of 1, 2, or 3) were randomly assigned to receive four more cycles of ABVD versus four cycles of AVD (doxorubicin, vinblastine, and dacarbazine). › The patients with positive PET-CT scan results (Deauville score of 4 or 5) after two cycles of ABVD received BEACOPP.

With a median follow-up of 41 months for the 172 patients with positive PET-CT results, the 3-year PFS rate was 67.5% and the OS rate was 87.8%

This trial did not establish that switching to BEACOPP was superior to remaining on ABVD.

In a nonrandomized trial (SWOG S0816 [NCT00822120]), 336 patients with advanced HL received two cycles of ABVD and then were evaluated by PET scan.[27] PET2–negative patients (Deauville score of 1 to 3) completed four more cycles of ABVD, while the 60 PET2–positive patients (18% of total) were switched to escalated BEACOPP.

Sources: SWOG S0816 · 27

In a nonrandomized trial (SWOG S0816 [NCT00822120]), 336 patients with advanced HL received two cycles of ABVD and then were evaluated by PET scan.[27] PET2–negative patients (Deauville score of 1 to 3) completed four more cycles of ABVD, while the 60 PET2–positive patients (18% of total) were switched to escalated BEACOPP.

With a median follow-up of 5.9 years, the 5-year PFS rate for the PET2–positive patients was 66% (95% CI, 52%–76%).[27][Level of evidence C3]

Sources: 27 · Level of evidence C3

Older patients with advanced-stage HL have also been studied.

In a multicenter phase II study, 48 patients older than 60 years, of whom 81% had advanced-stage disease, received brentuximab vedotin for two consecutive doses, followed by six cycles of AVD, followed by four more doses of brentuximab vedotin.[28]

Sources: 28

In a multicenter phase II study, 48 patients older than 60 years, of whom 81% had advanced-stage disease, received brentuximab vedotin for two consecutive doses, followed by six cycles of AVD, followed by four more doses of brentuximab vedotin.[28]

The 2-year event-free survival rate was 80%, PFS rate was 84%, and OS rate was 93%.[28][Level of evidence C3]

Sources: 28 · Level of evidence C3

Grade 3 or 4 toxicity was experienced by 42% of patients.

Summary of advanced-stage classic HL:

For patients with advanced-stage HL, six cycles of N-AVD is now the standard approach. In situations where immunotherapy might be contraindicated (such as active vasculitis or inflammatory colitis), BV-AVD is a good option.

When the financial toxicity of N-AVD or BV-AVD precludes their use (such as in a nation with constrained health care options), ABVD is still a reasonable and cost-effective approach. For patients with negative PET-CT scan results after the second cycle of ABVD, bleomycin may be omitted from the chemotherapy regimen with little loss of efficacy and improvement in tolerability.

Health professional

Treatment of Recurrent Classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

More than one-half of all patients with recurrent Hodgkin lymphoma (HL) can achieve long-term disease-free survival (DFS), or even cure, using reinduction therapy followed by stem cell/bone marrow transplant consolidation.[1] In this regard, the disease follows a 75% rule: 75% of patients attain a clinical complete remission with salvage therapy reinduction, and then 75% of patients who undergo autologous stem cell transplant (SCT) are free of disease at 4 years. Poor prognostic factors include:[2-4]

Sources: 1 · 2 · 4

Primary refractory disease (worst prognosis).

Relapse less than 12 months after initial therapy. Among patients who initially present with early-stage favorable disease that relapses, more than 75% have a relapse more than 12 months after diagnosis.[5]

Sources: 5

Inability to attain a clinical complete remission after reinduction (i.e., positron emission tomography‒computed tomography [PET-CT] scan results are positive with a Deauville score of 4 or 5 followed by subsequent progression in the size and/or sites of disease).

B symptoms at relapse.

Sources: B symptoms

Extranodal disease at relapse.

More than two previous salvage regimens received.

Health professional · Treatment of Recurrent Classic HL

Treatment Options for Recurrent Classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for recurrent classic HL include:

Pembrolizumab or nivolumab (alone or with chemotherapy).

Sources: Pembrolizumab or nivolumab (alone or with chemotherapy)

Brentuximab vedotin.

Sources: Brentuximab vedotin

Brentuximab vedotin plus nivolumab.

Sources: Brentuximab vedotin plus nivolumab

Chemotherapy with stem cell transplant.

Sources: Chemotherapy with stem cell transplant

Combination chemotherapy.

Sources: Combination chemotherapy

Radiation therapy.

Sources: Radiation therapy

Health professional · Treatment of Recurrent Classic HL / Treatment Options for Recurrent Classic HL

Pembrolizumab or nivolumab (alone or with chemotherapy)

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The anti-programmed cell death-1 (PD-1) monoclonal antibodies pembrolizumab and nivolumab are immune checkpoint inhibitors.

Evidence: (pembrolizumab):

In a phase II trial of 37 patients with relapsed or refractory disease, patients received three cycles of pembrolizumab with two cycles of ICE chemotherapy (ifosfamide, carboplatin, and etoposide) every 21 days prior to autologous SCT.[6][Level of evidence C3]

Sources: 6 · Level of evidence C3

In a phase II trial of 37 patients with relapsed or refractory disease, patients received three cycles of pembrolizumab with two cycles of ICE chemotherapy (ifosfamide, carboplatin, and etoposide) every 21 days prior to autologous SCT.[6][Level of evidence C3]

The complete response rate was 86.5% (95% confidence interval [CI], 71.2%–95.5%), and the overall response rate was 97.3%. There was no impairment in stem cell mobilization.

A phase II trial included 39 patients with transplant-eligible relapsed or refractory disease. Patients received pembrolizumab with GVD chemotherapy (gemcitabine, vinorelbine, and liposomal doxorubicin).[7]

Sources: 7

A phase II trial included 39 patients with transplant-eligible relapsed or refractory disease. Patients received pembrolizumab with GVD chemotherapy (gemcitabine, vinorelbine, and liposomal doxorubicin).[7]

With a median follow-up of 13.5 months, the overall response rate was 100%, and the complete response rate was 95%.[7][Level of evidence C3]

Sources: 7 · Level of evidence C3

Thirty-six patients (35%) proceeded to autologous SCT consolidation.

A prospective randomized trial included 304 patients with relapsed or refractory disease who were ineligible for or had a relapse after autologous SCT. Patients were assigned to receive either pembrolizumab or brentuximab vedotin.[8]

Sources: 8

A prospective randomized trial included 304 patients with relapsed or refractory disease who were ineligible for or had a relapse after autologous SCT. Patients were assigned to receive either pembrolizumab or brentuximab vedotin.[8]

With a median follow-up of 25.7 months, the median progression-free survival (PFS) for patients who received pembrolizumab was 13.2 months (95% CI, 10.9–19.4) versus 8.3 months (95% CI, 5.7–8.8) for patients who received brentuximab vedotin (hazard ratio [HR], 0.65; 95% CI, 0.48–0.88; P = .0027).[8][Level of evidence B1]

Sources: 8 · Level of evidence B1

Serious treatment-related adverse events occurred in 16% of patients who received pembrolizumab and 11% of patients who received brentuximab vedotin.

Studies of patients with relapsed HL treated with pembrolizumab reported the following:[9,10][Level of evidence C3]

Sources: 9 · 10 · Level of evidence C3

Studies of patients with relapsed HL treated with pembrolizumab reported the following:[9,10][Level of evidence C3]

The overall response rate was 64% to 74%, with a complete response rate of 22.4% (95% CI, 6.9%–28.6%).

Pembrolizumab was well tolerated by patients and can be used to achieve a clinical complete remission before autologous or allogeneic SCT.

The U.S. Food and Drug Administration (FDA) approved pembrolizumab for use in cases of refractory disease or relapse after three or more lines of therapy.

Evidence (nivolumab alone or nivolumab plus ICE):

Studies of patients with relapsed HL treated with nivolumab reported the following:[11-13][Level of evidence C3]

Sources: 11 · 13 · Level of evidence C3

Studies of patients with relapsed HL treated with nivolumab reported the following:[11-13][Level of evidence C3]

The overall response rate was 65% to 87% and the complete response rate was 16% to 28%, with response durations usually exceeding 1 year for patients with heavily pretreated, relapsed disease.

Nivolumab was well tolerated by patients and can be used to achieve a clinical complete remission before autologous or allogeneic SCT.

The FDA approved nivolumab for use after both relapse from SCT and previous exposure to brentuximab vedotin. Nivolumab is also approved if the patient has received three different previous treatments, including SCT.

In a phase II trial, nivolumab was given for 3 months. Patients who achieved a complete response proceeded to autologous SCT, while patients with disease in partial response or less received NICE (nivolumab, ifosfamide, carboplatin, and etoposide).[14]

Sources: 14

In a phase II trial, nivolumab was given for 3 months. Patients who achieved a complete response proceeded to autologous SCT, while patients with disease in partial response or less received NICE (nivolumab, ifosfamide, carboplatin, and etoposide).[14]

Nivolumab induction was given to 34 patients, and 9 patients needed NICE because the complete response rate was 71% for nivolumab. After all therapy, the overall response rate was 93%, and the complete response rate was 91%. The 2-year PFS rate was 72%, and the 2-year OS rate was 95%.[14][Level of evidence C3]

Sources: 14 · Level of evidence C3

Health professional · Treatment of Recurrent Classic HL / Treatment Options for Recurrent Classic HL

Brentuximab vedotin

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Brentuximab vedotin is an antibody-drug conjugate directed against CD30.[15-17] CD30 is a target for therapy because it is expressed on malignant Reed-Sternberg cells of HL but has limited expression on normal cells. Brentuximab vedotin is well tolerated by patients and can be used to achieve a clinical complete response before autologous or allogeneic SCT.

Sources: 15 · 17

Evidence (brentuximab vedotin):

In multiple trials for patients with relapsed disease, including one trial performed after allogeneic SCT, the following results were observed:

In multiple trials for patients with relapsed disease, including one trial performed after allogeneic SCT, the following results were observed:

For patients with relapsing disease, response rates were approximately 75%. Complete remission rates were approximately 50% and median PFS was 4 to 8 months.[15-19][Level of evidence C3]

Sources: 15 · 19 · Level of evidence C3

Twenty-seven previously untreated patients older than 60 years, judged by the investigator to be in poor condition and unable to undergo chemotherapy, received brentuximab vedotin.[20]

Sources: 20

Twenty-seven previously untreated patients older than 60 years, judged by the investigator to be in poor condition and unable to undergo chemotherapy, received brentuximab vedotin.[20]

A 92% overall response rate and 73% complete remission rate were reported.[20][Level of evidence C3]

Sources: 20 · Level of evidence C3

Retreatment with brentuximab vedotin was successful in patients with relapsed disease, with a response rate of 60%.[21][Level of evidence C3]

Sources: 21 · Level of evidence C3

For 329 patients at high risk of residual HL after SCT, the double-blind AETHERA trial (NCT01100502) evaluated brentuximab vedotin versus placebo.[22,23]

Sources: AETHERA · 22 · 23

For 329 patients at high risk of residual HL after SCT, the double-blind AETHERA trial (NCT01100502) evaluated brentuximab vedotin versus placebo.[22,23]

With a median follow-up of 5.0 years, the 5-year PFS rate for brentuximab vedotin was 59% (95% CI, 51%–66%) versus 41% (95% CI, 33%–49%) for placebo (HR, 0.521; 95% CI, 0.379–0.717).[22,23][Level of evidence B1]

Sources: 22 · 23 · Level of evidence B1

The 16-month treatment duration after transplant was not achieved by most patients because they developed progressive peripheral neuropathy, which was partially reversible after discontinuation of brentuximab vedotin.

In two phase I/II studies, 120 patients with relapsed or refractory HL received brentuximab vedotin and bendamustine.[24]

Sources: 24

In two phase I/II studies, 120 patients with relapsed or refractory HL received brentuximab vedotin and bendamustine.[24]

After two cycles, the objective response rates were 93% and 78%, and the complete remission rates were 74% and 32%.[24,25][Level of evidence C3]

Sources: 24 · 25 · Level of evidence C3

Health professional · Treatment of Recurrent Classic HL / Treatment Options for Recurrent Classic HL

Brentuximab vedotin plus nivolumab

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Evidence (brentuximab vedotin plus nivolumab):

In a phase II trial, 91 patients with relapsed or refractory HL received brentuximab vedotin and nivolumab.[26] Prior brentuximab vedotin therapy was allowed if the patient was not resistant or intolerant to the drug.

Sources: 26

In a phase II trial, 91 patients with relapsed or refractory HL received brentuximab vedotin and nivolumab.[26] Prior brentuximab vedotin therapy was allowed if the patient was not resistant or intolerant to the drug.

With a median follow-up of 34.3 months, the overall response rate was 85%, and the complete response rate was 67%. The 3-year PFS rate was 77% (95% CI, 65%–86%) for all patients and 91% (95% CI, 79%–96%) for those who received autologous SCT. The 3-year OS rate was 93% (95% CI, 85%–97%).[26][Level of evidence C3]

Sources: 26 · Level of evidence C3

In this trial, 16% of patients had adverse events that required treatment with steroids.

In a phase I/II study of 59 patients with relapsed or refractory HL, the combination of nivolumab and brentuximab vedotin was well tolerated (<10% of patients required systemic steroids).[27][Level of evidence C3]

Sources: 27 · Level of evidence C3

In a phase I/II study of 59 patients with relapsed or refractory HL, the combination of nivolumab and brentuximab vedotin was well tolerated (<10% of patients required systemic steroids).[27][Level of evidence C3]

With a median follow-up of 28.9 months, the 18-month PFS rate was 94% (95% CI, 84%–98%).

Adverse events included peripheral neuropathy (53%), neutropenia (42%), and immune-related events requiring corticosteroids (29%).[27]

Sources: 27

Health professional · Treatment of Recurrent Classic HL / Treatment Options for Recurrent Classic HL

Chemotherapy with stem cell transplant

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Patients whose HL relapses after initial combination chemotherapy can undergo reinduction with the same or another chemotherapy regimen followed by high-dose chemotherapy and autologous bone marrow or peripheral stem cell or allogeneic bone marrow rescue.[1,28-31] This therapy has resulted in 3- to 4-year DFS rates of up to 50%. Patients who are responsive to reinduction therapy may have a better prognosis after subsequent autologous SCT; in one analysis, the 3-year event-free survival (EFS) rate was 80% with negative PET-CT scan results and 29% with positive PET-CT scan results.[32]

Sources: 1 · 28 · 31 · 32

Patients who do not respond to induction chemotherapy (about 20%‒25% of all presenting patients) have survival rates lower than 10% at 8 years.[3] For these patients, high-dose chemotherapy and autologous bone marrow or peripheral stem cell or allogeneic bone marrow rescue [28,29,33-35] have resulted in 5-year DFS rates of around 25% to 30%, but selection bias clearly influences these numbers.[28,29,34,36,37]

Sources: 3 · 28 · 29 · 33 · 35 · 28 · 29 · 34 · 36 · 37

In a retrospective review of 105 patients, those older than 60 years fared better with a combination of chemotherapy and salvage radiation therapy than with the use of intensified transplant consolidation.[38][Level of evidence C3]

Sources: 38 · Level of evidence C3

The use of HLA-matched sibling marrow (allogeneic transplant) results in lower relapse rates, but the benefit may be offset by increased toxic effects.[28,39,40] Reduced-intensity conditioning for allogeneic SCT is also under clinical evaluation.[41-43]

Sources: 28 · 39 · 40 · 41 · 43

Evidence (chemotherapy with SCT):

A randomized trial compared aggressive conventional chemotherapy versus high-dose chemotherapy with autologous hematopoietic SCT for relapsed chemosensitive HL.[44][Level of evidence B1]

Sources: 44 · Level of evidence B1

A randomized trial compared aggressive conventional chemotherapy versus high-dose chemotherapy with autologous hematopoietic SCT for relapsed chemosensitive HL.[44][Level of evidence B1]

This trial showed improvement in freedom from treatment failure at 3 years for the transplant arm (55%) versus the chemotherapy-alone arm (34%).[44]

Sources: 44

No difference was observed in overall survival (OS).

A Cochrane meta-analysis concluded that autologous SCT after reinduction chemotherapy improves relapse-free survival by 20% to 30% over chemotherapy alone, but without an OS benefit.[45][Level of evidence B1]

Sources: 45 · Level of evidence B1

In three retrospective reviews of patients who underwent autologous bone marrow transplant (BMT) for relapsed or refractory disease, a comparison was made between those who received involved-field radiation therapy (IFRT) for residual masses after high-dose therapy and those who received no further treatment.[46-48]

Sources: 46 · 48

In three retrospective reviews of patients who underwent autologous bone marrow transplant (BMT) for relapsed or refractory disease, a comparison was made between those who received involved-field radiation therapy (IFRT) for residual masses after high-dose therapy and those who received no further treatment.[46-48]

Those who received IFRT had decreased local disease recurrence.

Normalization of fluorine F 18-fludeoxyglucose PET-CT scans after reinduction therapy predicted a much better outcome after SCT, with an EFS rate of 80% versus 29% in one phase II trial.[32][Level of evidence C2]

Sources: 32 · Level of evidence C2

After completion of autologous SCT for recurrent HL, 329 patients were randomly assigned to receive brentuximab vedotin or placebo in a double-blind trial (AETHERA [NCT01100502]).[22,23]

Sources: AETHERA · 22 · 23

With a median follow-up of 5.0 years, the 5-year PFS rate for brentuximab vedotin was 59% (95% CI, 51%–66%) versus 41% (95% CI, 33%–49%) for placebo (HR, 0.521; 95% CI, 0.379–0.717).[22,23][Level of evidence B1]

Sources: 22 · 23 · Level of evidence B1

The 16-month treatment duration after transplant was not achieved by most patients because they developed progressive peripheral neuropathy, which was partially reversible after discontinuation of brentuximab vedotin.

It is unclear whether the results of this trial are applicable when brentuximab vedotin is employed before transplant, such as during reinduction after relapse or during initial therapy (presently under clinical evaluation).

A phase II trial reported a response rate higher than 50% for patients with relapsing disease after autologous BMT.[49][Level of evidence C3] For patients with recurrent disease after autologous BMT, weekly vinblastine therapy has provided palliation with minimal toxic effects.[50][Level of evidence C3]

Sources: 49 · Level of evidence C3 · 50 · Level of evidence C3

Health professional · Treatment of Recurrent Classic HL / Treatment Options for Recurrent Classic HL

Combination chemotherapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For patients who experience a relapse after initial combination chemotherapy, prognosis is determined more by the duration of the first remission than by the specific induction or salvage combination chemotherapy regimen. Patients whose initial remission after chemotherapy was longer than 1 year (late relapse) have long-term survival rates of 22% to 71% with salvage chemotherapy.[2-4,51-53] Patients whose initial remission after chemotherapy was shorter than 1 year (early relapse) do much worse and have long-term survival rates of 11% to 46%.[2,3,54]

Sources: 2 · 4 · 51 · 53 · 2 · 3 · 54

It is rare to see a patient who received only radiation therapy for initial treatment, but patients who experience a relapse after initial wide-field, high-dose radiation therapy have a good prognosis. Combination chemotherapy results in 10-year DFS rates of 57% to 81% and OS rates of 57% to 89%.[2,55-57]

Sources: 2 · 55 · 57

Health professional · Treatment of Recurrent Classic HL / Treatment Options for Recurrent Classic HL

Radiation therapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For the small subgroup of patients with only limited nodal recurrence following initial chemotherapy, radiation therapy with or without additional chemotherapy may provide long-term survival for about 50% of these highly selected patients.[58,59]

Sources: 58 · 59

Health professional · Treatment of Recurrent Classic HL / Treatment Options for Recurrent Classic HL

Summary for sequencing therapies for recurrent classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Patients whose disease recurs who have not received brentuximab vedotin or a checkpoint inhibitor should consider the combination of nivolumab and brentuximab vedotin.[26,60]

Sources: 26 · 60

The combination of pembrolizumab plus ICE chemotherapy,[6] nivolumab plus ICE chemotherapy,[14] or pembrolizumab plus GVD chemotherapy [7] is an effective induction therapy prior to autologous SCT.

Sources: 6 · 14 · 7

Consider allogeneic SCT for patients with primary refractory disease who achieved partial response or complete remission on salvage therapy.

Checkpoint inhibitors alone are useful palliative agents for older patients or patients with comorbidities that preclude SCT.

Health professional

Treatment of Nodular Lymphocyte–Predominant HL (NLPHL)

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Immunophenotypic differences distinguish NLPHL (CD15-, CD20+, CD30-) from lymphocyte-rich classic Hodgkin lymphoma (HL) (CD15+, CD20-, CD30+).[1,2] The largest retrospective report of 426 cases showed no significant difference in clinical response or outcome to standard therapies for these two subgroups when patients present with early-stage disease (stage I or II).[3][Level of evidence C1]

Sources: 1 · 2 · 3 · Level of evidence C1

Patients with NLPHL have earlier-stage disease and longer survival than those with classic HL.[4,5] NLPHL is usually diagnosed in asymptomatic younger patients with cervical or inguinal lymph nodes; this usually occurs without mediastinal involvement. Unlike patients with classic HL, bulky disease, B symptoms, and contiguous spread are uncommon in patients with NLPHL.[6,7] An international prognostic score identified age 45 years or older, stage III or IV disease, hemoglobin less than 10.5 g/dL, and splenic involvement as poor prognostic factors for NLPHL.[8]

Sources: 4 · 5 · 6 · 7 · 8

Health professional · Treatment of Nodular Lymphocyte–Predominant HL (NLPHL)

Treatment Options for NLPHL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for NLPHL include:

Watchful waiting/active surveillance.

Sources: Watchful waiting/active surveillance

Radiation therapy (early stage).

Sources: Radiation therapy (early stage)

Chemotherapy (advanced stage).

Sources: Chemotherapy (advanced stage)

Rituximab.

Sources: Rituximab

Health professional · Treatment of Nodular Lymphocyte–Predominant HL (NLPHL) / Treatment Options for NLPHL

Watchful waiting/active surveillance

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Because of the favorable prognosis for NLPHL and the potential long-term side effects of therapy, studies have evaluated watchful waiting or active surveillance for patients with asymptomatic, low tumor burden disease.[9] In a retrospective comparison, 37 such patients managed with active surveillance had a 5-year progression-free survival (PFS) rate of 77%, versus 85% for patients receiving active treatment.[10][Level of evidence C3]

Sources: 9 · 10 · Level of evidence C3

Health professional · Treatment of Nodular Lymphocyte–Predominant HL (NLPHL) / Treatment Options for NLPHL

Radiation therapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Limited-field radiation therapy is the most-common treatment approach for patients with early-stage disease. This histology is rare, but this approach is based on retrospective analysis spanning several decades.[5,11-15]

Sources: 5 · 11 · 15

Patients with nonbulky lymphocyte–predominant disease presenting in unilateral high neck (above the thyroid notch) or epitrochlear locations require only involved-field radiation therapy (IFRT) after clinical staging.[16] A retrospective report of 426 cases of lymphocyte-predominant HL (including the nodular lymphocyte–predominant and lymphocyte-rich classic subtypes) showed that more patients died of acute and long-term treatment-related toxicity than of recurrent HL.[3][Level of evidence C1] Limitation of radiation dose and radiation fields and avoidance of leukemogenic chemotherapeutic agents, along with watchful waiting policies, should be investigated for these subgroups.[15,17]

Sources: 16 · 3 · Level of evidence C1 · 15 · 17

Health professional · Treatment of Nodular Lymphocyte–Predominant HL (NLPHL) / Treatment Options for NLPHL

Chemotherapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For patients with early-stage NLPHL, ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for two to three cycles has been combined with IFRT on the basis of anecdotal single-arm trials.[5,18]

Sources: 5 · 18

For patients with advanced-stage NLPHL, chemotherapy regimens designed for patients with non-Hodgkin lymphomas, such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone), may be preferred, based on two retrospective reviews and a phase II study.[7,19-21][Level of evidence C3]

Sources: 7 · 19 · 21 · Level of evidence C3

Health professional · Treatment of Nodular Lymphocyte–Predominant HL (NLPHL) / Treatment Options for NLPHL

Rituximab

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

In a phase II trial of 39 patients with previously untreated and relapsed NLPHL, most of whom had advanced-stage disease, treatment with rituximab yielded a 100% response rate. With a median follow-up of 9.8 years, the median PFS was 3.0 years for patients who received rituximab induction only and 5.6 years for patients who received rituximab induction plus rituximab maintenance.[22][Level of evidence C2] With induction only, 9 of 23 patients had disease relapse with an aggressive B-cell lymphoma.

Sources: 22 · Level of evidence C2

Health professional · Treatment of Nodular Lymphocyte–Predominant HL (NLPHL)

Follow-Up

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Despite a usually favorable prognosis, there is a tendency for histological transformation of NLPHL to diffuse large B-cell lymphoma or T-cell–rich large B-cell lymphoma in approximately 10% of patients by 10 years.[6,22,23] This propensity of NLPHL to transform to aggressive B-cell lymphoma underscores the importance of long-term follow-up and rebiopsy at relapse.[22,24]

Sources: 6 · 22 · 23 · 22 · 24

With a median follow-up of 7 to 8 years, more patients died of treatment-related toxic effects (acute and long-term) than of recurrent HL. Limitation of radiation dose and fields and avoidance of leukemogenic chemotherapeutic agents, along with watchful waiting policies, should be investigated for these subgroups.[5,17,25]

Sources: 5 · 17 · 25

The treatment approach for relapsing disease is similar to that for recurrent follicular lymphoma. Based on age and performance status, some patients receive sequential therapies and watchful waiting, and some patients receive aggressive salvage chemoimmunotherapy (like R-ICE [rituximab, ifosfamide, carboplatin, and etoposide]) followed by stem cell transplant.[7,26,27]

Sources: 7 · 26 · 27

For patients · General Information About Hodgkin Lymphoma

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

The prognosis and treatment options depend on:

Sources: prognosis

The patient's signs and symptoms, including whether or not they have B symptoms (fever for no known reason, weight loss for no known reason, or drenching night sweats).

The stage of the cancer (the size of the cancer tumors and whether the cancer has spread to the abdomen or more than one group of lymph nodes).

The type of Hodgkin lymphoma.

Blood test results.

Sources: Blood test

The patient's age, sex, and general health.

Whether the cancer is newly diagnosed, continues to grow during treatment, or has come back after treatment.

For Hodgkin lymphoma during pregnancy, treatment options also depend on:

The wishes of the patient.

The age of the fetus.

Hodgkin lymphoma can usually be cured if found and treated early.

Sources: cured

For patients · Stages of Hodgkin Lymphoma

Hodgkin lymphoma may be grouped for treatment as follows:

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For patients · Stages of Hodgkin Lymphoma / Hodgkin lymphoma may be grouped for treatment as follows:

Early Favorable

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Early favorable Hodgkin lymphoma is stage I or stage II, without risk factors that increase the chance that the cancer will come back after it is treated.

Sources: stage I · stage II · risk factors

For patients · Stages of Hodgkin Lymphoma / Hodgkin lymphoma may be grouped for treatment as follows:

Early Unfavorable

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Early unfavorable Hodgkin lymphoma is stage I or stage II with one or more of the following risk factors that increase the chance that the cancer will come back after it is treated:

Sources: stage I · stage II · risk factors

Having a tumor in the chest that is larger than 1/3 of the width of the chest or is at least 10 centimeters.

Sources: tumor · centimeters

Having cancer in an organ other than the lymph nodes.

Sources: lymph nodes

Having a high sedimentation rate (in a sample of blood, the red blood cells settle to the bottom of the test tube more quickly than normal).

Sources: sedimentation rate · blood · red blood cells

Having three or more lymph nodes with cancer.

Having B symptoms (fever for no known reason, weight loss for no known reason, or drenching night sweats).

Sources: fever

For patients · Stages of Hodgkin Lymphoma / Hodgkin lymphoma may be grouped for treatment as follows:

Advanced

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Advanced Hodgkin lymphoma is stage III or stage IV. Advanced favorable Hodgkin lymphoma means that the patient has 0–3 of the risk factors below. Advanced unfavorable Hodgkin lymphoma means that the patient has 4 or more of the risk factors below. The more risk factors a patient has, the more likely it is that the cancer will come back after it is treated:

Sources: stage III · stage IV · risk factors

Having a low blood albumin level (below 4).

Sources: albumin

Having a low hemoglobin level (below 10.5).

Sources: hemoglobin

Being male.

Being aged 45 years or older.

Having stage IV disease.

Having a high white blood cell count (15,000 or higher).

Sources: white blood cell

Having a low lymphocyte count (below 600 or less than 8% of the white blood cell count).

Sources: lymphocyte

For patients · Stages of Hodgkin Lymphoma

Hodgkin lymphoma can recur (come back) after it has been treated.

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

The cancer may come back in the lymph system or in other parts of the body.

Sources: lymph system

For patients

Treatment Option Overview

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

There are different types of treatment for patients with Hodgkin lymphoma.

Patients with Hodgkin lymphoma should have their treatment planned by a team of health care providers with expertise in treating lymphomas.

Treatment for Hodgkin lymphoma may cause side effects.

The following types of treatment are used:

The following types of treatment are used:

Chemotherapy

Radiation therapy

Targeted therapy

Immunotherapy

Chemotherapy with stem cell transplant

For patients with nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), treatment options also include:

For patients with nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), treatment options also include:

Watchful waiting

Active surveillance

For pregnant patients with Hodgkin lymphoma, treatment options also include:

For pregnant patients with Hodgkin lymphoma, treatment options also include:

Watchful waiting

Steroid therapy

New types of treatment are being tested in clinical trials.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with Hodgkin lymphoma.

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Different types of treatment are available for patients with Hodgkin lymphoma. Some treatments are standard (currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: Hodgkin lymphoma · standard · clinical trials · research study

For pregnant women with Hodgkin lymphoma, treatment is carefully chosen to protect the fetus. Treatment decisions are based on the mother's wishes, the stage of the Hodgkin lymphoma, and the trimester of the pregnancy. The treatment plan may change as the signs and symptoms, cancer, and pregnancy change. Choosing the most appropriate cancer treatment is a decision that ideally involves the patient, family, and health care team.

Sources: fetus · stage · signs · symptoms

For patients · Treatment Option Overview

Patients with Hodgkin lymphoma should have their treatment planned by a team of health care providers with expertise in treating lymphomas.

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Treatment will be overseen by a medical oncologist, a doctor who specializes in treating cancer. The medical oncologist may refer you to other health care providers who have experience and expertise in treating Hodgkin lymphoma and who specialize in certain areas of medicine. These may include the following specialists:

Sources: medical oncologist

Radiation oncologist.

Sources: Radiation oncologist

Rehabilitation specialist.

Sources: Rehabilitation specialist

Hematologist.

Sources: Hematologist

Fertility specialist.

Sources: Fertility specialist

Other oncology specialists.

Sources: oncology

For patients · Treatment Option Overview

Treatment for Hodgkin lymphoma may cause side effects.

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Treatment with chemotherapy and/or radiation therapy for Hodgkin lymphoma may increase the risk of second cancers and other health problems for many months or years after treatment. These late effects depend on the type of treatment and the patient's age when treated, and may include:

Sources: late effects · chemotherapy · radiation therapy · second cancers

Second cancers.

Second cancers.

Solid tumors, such as mesothelioma and cancer of the lung, breast, thyroid, bone, soft tissue, stomach, esophagus, colon, rectum, cervix, and head and neck.

Sources: Solid tumors · mesothelioma · lung · breast · thyroid · bone · soft tissue · stomach · esophagus · colon · rectum · cervix · head and neck

Acute myelogenous leukemia.

Sources: Acute myelogenous leukemia

Infertility.

Sources: Infertility

Hypothyroidism (too little thyroid hormone in the blood).

Sources: Hypothyroidism · thyroid hormone · blood

Heart disease, such as heart attack.

Sources: Heart disease

Lung problems, such as trouble breathing.

Sources: Lung

Avascular necrosis of bone (death of bone cells caused by lack of blood flow).

Sources: Avascular necrosis

Severe infection.

Sources: infection

Chronic fatigue.

Sources: Chronic fatigue

Cognitive impairment.

Sources: Cognitive impairment

Regular follow-up by doctors who are experts in finding and treating late effects is important for the long-term health of patients treated for Hodgkin lymphoma.

Sources: follow-up

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses one or more drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Cancer treatment using more than one chemotherapy drug is called combination chemotherapy. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: injected · systemic chemotherapy

When a pregnant woman is treated with chemotherapy for Hodgkin lymphoma, it isn't possible to protect the fetus from being exposed to the chemotherapy. Some chemotherapy regimens may cause birth defects if given in the first trimester. Vinblastine is an anticancer drug that has not been linked with birth defects when given in the second or third trimester of pregnancy.

Sources: regimens · Vinblastine · anticancer

For more information, see Drugs Approved for Hodgkin Lymphoma.

Sources: Drugs Approved for Hodgkin Lymphoma

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Sometimes total-body irradiation is given before a stem cell transplant.

Sources: x-rays · radiation · External radiation therapy · total-body irradiation · stem cell transplant

Proton beam radiation therapy is a type of high-energy, external radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. This type of treatment can lower the amount of radiation damage to healthy tissue near a tumor such as the heart or breast.

Sources: Proton beam radiation therapy

External radiation therapy is used to treat Hodgkin lymphoma and may also be used as palliative therapy to relieve symptoms and improve quality of life.

Sources: palliative therapy · quality of life

For a pregnant woman with Hodgkin lymphoma, radiation therapy should be postponed until after delivery, if possible, to avoid any risk of radiation exposure during fetal development. If treatment is needed right away, the woman may decide to continue the pregnancy and receive radiation therapy. A lead shield is used to cover the pregnant woman's abdomen to help protect the fetus from radiation as much as possible.

Sources: fetal · lead shield · abdomen

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.

Sources: Targeted therapy

Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Brentuximab vedotin and rituximab are monoclonal antibodies used to treat Hodgkin lymphoma.

Sources: Monoclonal antibodies · immune system · proteins · antibodies · infusion · toxins · radioactive · Brentuximab vedotin · rituximab

For more information, see Drugs Approved for Hodgkin Lymphoma.

Sources: Drugs Approved for Hodgkin Lymphoma

For patients · Treatment Option Overview / The following types of treatment are used:

Immunotherapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.

Sources: Immunotherapy

PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body's immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells. Pembrolizumab and nivolumab are types of PD-1 inhibitors used to treat Hodgkin lymphoma that has recurred (come back).

Sources: PD-1 · PD-L1 · T cells · immune responses · Pembrolizumab · nivolumab · recurred

For more information, see Drugs Approved for Hodgkin Lymphoma.

Sources: Drugs Approved for Hodgkin Lymphoma

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy with stem cell transplant

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy and radiation therapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: doses · Stem cells · bone marrow · donor

For patients · Treatment Option Overview

For patients with nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), treatment options also include:

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / For patients with nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), treatment options also include:

Watchful waiting

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Watchful waiting is closely monitoring a patient's condition without giving any treatment until signs or symptoms appear or change.

For patients · Treatment Option Overview / For patients with nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), treatment options also include:

Active surveillance

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Active surveillance is a treatment plan that involves closely watching a patient's condition but not giving any treatment unless there are changes in test results that show the condition is getting worse. During active surveillance, certain exams and tests are done on a regular schedule.

For patients · Treatment Option Overview

For pregnant patients with Hodgkin lymphoma, treatment options also include:

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / For pregnant patients with Hodgkin lymphoma, treatment options also include:

Watchful waiting

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Watchful waiting is closely monitoring a patient's without giving any treatment unless signs or symptoms appear or change. Labor may be induced when the fetus is 32 to 36 weeks so that the mother can begin treatment.

For patients · Treatment Option Overview / For pregnant patients with Hodgkin lymphoma, treatment options also include:

Steroid therapy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Steroids are hormones made naturally in the body by the adrenal glands and by reproductive organs. Some types of steroids are made in a laboratory. Certain steroid drugs have been found to help chemotherapy work better and help stop the growth of cancer cells. When an early delivery is likely, steroids can also help the lungs of the fetus develop faster than normal. This gives babies who are born early a better chance of survival.

Sources: hormones · adrenal glands · reproductive organs

For more information, see Drugs Approved for Hodgkin Lymphoma.

Sources: Drugs Approved for Hodgkin Lymphoma

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Early Favorable Classic Hodgkin Lymphoma

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of early favorable classic Hodgkin lymphoma in adults may include:

Sources: classic Hodgkin lymphoma

Combination chemotherapy with or without radiation therapy to the areas of the body with cancer.

Sources: Combination chemotherapy · radiation therapy · cancer

Radiation therapy alone in patients who cannot be treated with combination chemotherapy.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Early Unfavorable Classic Hodgkin Lymphoma

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of early unfavorable classic Hodgkin lymphoma in adults may include:

Sources: classic Hodgkin lymphoma

Combination chemotherapy with or without radiation therapy to the areas of the body with cancer.

Sources: Combination chemotherapy · radiation therapy

Targeted therapy with a monoclonal antibody (brentuximab vedotin) and combination chemotherapy with or without radiation therapy.

Sources: Targeted therapy · monoclonal antibody · brentuximab vedotin

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Advanced Classic Hodgkin Lymphoma

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of advanced classic Hodgkin lymphoma in adults may include:

Sources: classic Hodgkin lymphoma

Combination chemotherapy with or without immunotherapy (nivolumab) or targeted therapy (brentuximab vedotin).

Sources: Combination chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Classic Hodgkin Lymphoma

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of recurrent classic Hodgkin lymphoma in adults may include:

Sources: recurrent · classic Hodgkin lymphoma

Immunotherapy with an immune checkpoint inhibitor (pembrolizumab or nivolumab) with or without combination chemotherapy. This may be followed by stem cell transplant.

Sources: Immunotherapy · immune checkpoint inhibitor · pembrolizumab · nivolumab · combination chemotherapy · stem cell transplant

Targeted therapy with a monoclonal antibody (brentuximab vedotin) with or without immunotherapy with an immune checkpoint inhibitor (nivolumab).

Sources: Targeted therapy · monoclonal antibody · brentuximab vedotin

Combination chemotherapy with radiation therapy to the areas of the body with cancer for patients older than 60 years.

Radiation therapy with or without chemotherapy, for patients whose cancer came back only in the lymph nodes.

Sources: chemotherapy · lymph nodes

Immunotherapy as palliative therapy to relieve symptoms and improve quality of life.

Sources: palliative therapy · symptoms · quality of life

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Nodular Lymphocyte–Predominant Hodgkin Lymphoma (NLPHL)

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of NLPHL in adults may include:

Sources: NLPHL

Watchful waiting or active surveillance.

Sources: Watchful waiting · active surveillance

Radiation therapy to the areas of the body with cancer, for patients with early-stage NLPHL.

Sources: Radiation therapy · early-stage

Chemotherapy, for patients with advanced-stage NLPHL.

Sources: Chemotherapy · advanced-stage

Targeted therapy with a monoclonal antibody (rituximab).

Sources: Targeted therapy · monoclonal antibody · rituximab

For patients

Treatment of Hodgkin Lymphoma During Pregnancy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

For patients · Treatment of Hodgkin Lymphoma During Pregnancy

Hodgkin Lymphoma During the First Trimester of Pregnancy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

When Hodgkin lymphoma is diagnosed in the first trimester of pregnancy, it does not necessarily mean that the woman will be advised to end the pregnancy. Each woman's treatment will depend on the stage of the lymphoma, how fast it is growing, and her wishes. Treatment of Hodgkin lymphoma during the first trimester of pregnancy may include:

Sources: Hodgkin lymphoma · stage · lymphoma

Watchful waiting when the cancer is above the diaphragm and is slow-growing. Labor may be induced early so the mother can begin treatment.

Sources: Watchful waiting · diaphragm

Radiation therapy when the cancer is above the diaphragm. A lead shield is used to protect the fetus from the radiation as much as possible.

Sources: Radiation therapy · fetus · radiation

Chemotherapy using one or more drugs.

Sources: Chemotherapy

For patients · Treatment of Hodgkin Lymphoma During Pregnancy

Hodgkin Lymphoma During the Second or Third Trimester of Pregnancy

Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 27, 2025. Captured 2026-09-09.

When Hodgkin lymphoma is diagnosed in the second half of pregnancy, most women can delay treatment until after delivery. Treatment of Hodgkin lymphoma during the second or third trimester of pregnancy may include:

Sources: Hodgkin lymphoma

Watchful waiting, with plans to induce labor when the fetus is 32 to 36 weeks.

Sources: Watchful waiting · fetus

Radiation therapy to relieve breathing problems caused by a large tumor in the chest.

Sources: Radiation therapy

Combination chemotherapy using one or more drugs.

Sources: Combination chemotherapy

Steroid therapy.

Sources: Steroid therapy

Studies

Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

NCT00002561 · COMPLETED · phase3

Hodgkin Lymphoma

ClinicalTrials.gov record

Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

NCT00433433 · UNKNOWN · phase3

Lymphoma

ClinicalTrials.gov record

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

NCT00678327 · COMPLETED · phase3

Lymphoma

ClinicalTrials.gov record

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

NCT00822120 · COMPLETED · phase2

Lymphoma, Nonneoplastic Condition

ClinicalTrials.gov record

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

NCT00848926 · COMPLETED · phase2

Disease, Hodgkin

ClinicalTrials.gov record

PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma

NCT00943423 · ACTIVE NOT RECRUITING · phase3

Lymphoma

ClinicalTrials.gov record

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

NCT01100502 · COMPLETED · phase3

Disease, Hodgkin

ClinicalTrials.gov record

Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions

NCT01399931 · UNKNOWN · Phase not reported

Hodgkin's Lymphoma

ClinicalTrials.gov record

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

NCT01712490 · COMPLETED · phase3

Hodgkin Lymphoma

ClinicalTrials.gov record

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

NCT02181738 · COMPLETED · phase2

Hodgkin Disease

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

NCT02453594 · COMPLETED · phase2

Hodgkin Lymphoma

ClinicalTrials.gov record

A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

NCT02495922 · COMPLETED · phase3

Multiple Myeloma

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

NCT02684292 · COMPLETED · phase3

Hodgkin Lymphoma

ClinicalTrials.gov record

A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

NCT03722147 · COMPLETED · phase1, phase2

Hodgkin's Lymphoma

ClinicalTrials.gov record

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

NCT01771107 · COMPLETED · phase1, phase2

AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin...

ClinicalTrials.gov record

Disease and treatment settings

Adcetris: Hodgkin lymphoma after prior therapy

Disease and treatment setting

Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or after failure of at least 2 multi-agent chemotherapy regimens in patients who are not ASCT candidates

ADCETRIS: recurrent Hodgkin lymphoma after prior therapy

Disease and treatment setting

1.4 Relapsed Classical Hodgkin Lymphoma (cHL) ADCETRIS is indicated for the treatment of adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not...

advanced Hodgkin Lymphoma

Disease and treatment setting

Treatment of Advanced Classic HL

CARMUSTINE: metastatic Hodgkin's Lymphoma

Disease and treatment setting

1 INDICATIONS AND USAGE Carmustine for Injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors...

Gleostine: Hodgkin's Lymphoma after prior therapy

Disease and treatment setting

1.2 Hodgkin's Lymphoma Gleostine is indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin's lymphoma whose disease has progressed following initial chemotherapy.

Gleostine: Hodgkin's Lymphoma after prior therapy

Disease and treatment setting

( 1 ) Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy.

Hodgkin Lymphoma

Disease and treatment setting

Hodgkin Lymphoma

KEYTRUDA: refractory Hodgkin lymphoma

Disease and treatment setting

1.5 Classical Hodgkin Lymphoma KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

Lomustine: Hodgkin's Lymphoma after prior therapy

Disease and treatment setting

1.2 Hodgkin's Lymphoma Lomustine is indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin's lymphoma whose disease has progressed following initial chemotherapy.

Lomustine: Hodgkin's Lymphoma after prior therapy

Disease and treatment setting

( 1 ) Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy.

Opdivo: recurrent Hodgkin lymphoma

Disease and treatment setting

Treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after:Autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, Or3 or more lines of systemic therapy that includes...

Opdivo: recurrent Hodgkin lymphoma after prior therapy

Disease and treatment setting

For the treatment of classical Hodgkin Lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin

recurrent Hodgkin Lymphoma

Disease and treatment setting

Treatment of Recurrent Classic HL

Drug labels

ADCETRIS

Label date 2025-11-11

ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin,...

DailyMed label

Cyclophosphamide

Label date 2024-11-19

Cyclophosphamide is an alkylating drug indicated for treatment of: • Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple...

DailyMed label

Cyclophosphamide

Label date 2024-04-10

Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma...

DailyMed label

Cyclophosphamide

Label date 2020-08-07

Cyclophosphamide Tablets is an alkylating drug indicated for treatment of: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple...

DailyMed label

GALLIUM CITRATE GA-67

Label date 2025-08-13

INDICATIONS AND USAGE Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms...

DailyMed label